194 related articles for article (PubMed ID: 26443804)
1. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.
Mazor R; Zhang J; Xiang L; Addissie S; Awuah P; Beers R; Hassan R; Pastan I
Mol Cancer Ther; 2015 Dec; 14(12):2789-96. PubMed ID: 26443804
[TBL] [Abstract][Full Text] [Related]
2. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
3. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
Mazor R; Onda M; Park D; Addissie S; Xiang L; Zhang J; Hassan R; Pastan I
Oncotarget; 2016 May; 7(21):29916-26. PubMed ID: 27167198
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
[TBL] [Abstract][Full Text] [Related]
5. Improving the
Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
[TBL] [Abstract][Full Text] [Related]
6. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.
Mazor R; Eberle JA; Hu X; Vassall AN; Onda M; Beers R; Lee EC; Kreitman RJ; Lee B; Baker D; King C; Hassan R; Benhar I; Pastan I
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8571-6. PubMed ID: 24799704
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Hassan R; Alewine C; Mian I; Spreafico A; Siu LL; Gomez-Roca C; Delord JP; Italiano A; Lassen U; Soria JC; Bahleda R; Thomas A; Steinberg SM; Peer CJ; Figg WD; Niederfellner G; Méresse Naegelen V; Pastan I
Cancer; 2020 Nov; 126(22):4936-4947. PubMed ID: 32870522
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of therapeutic recombinant immunotoxins.
Mazor R; Onda M; Pastan I
Immunol Rev; 2016 Mar; 270(1):152-64. PubMed ID: 26864110
[TBL] [Abstract][Full Text] [Related]
9. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
Bera TK; Williams-Gould J; Beers R; Chowdhury P; Pastan I
Mol Cancer Ther; 2001 Dec; 1(2):79-84. PubMed ID: 12467225
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.
King EM; Mazor R; Çuburu N; Pastan I
J Immunol; 2018 Mar; 200(6):2038-2045. PubMed ID: 29431691
[TBL] [Abstract][Full Text] [Related]
11. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.
Hansen JK; Weldon JE; Xiang L; Beers R; Onda M; Pastan I
J Immunother; 2010 Apr; 33(3):297-304. PubMed ID: 20445350
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.
Bauss F; Lechmann M; Krippendorff BF; Staack R; Herting F; Festag M; Imhof-Jung S; Hesse F; Pompiati M; Kollmorgen G; da Silva Mateus Seidl R; Bossenmaier B; Lau W; Schantz C; Stracke JO; Brinkmann U; Onda M; Pastan I; Bosslet K; Niederfellner G
Mol Oncol; 2016 Oct; 10(8):1317-29. PubMed ID: 27507537
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of Immunotoxins Containing
Mazor R; Pastan I
Front Immunol; 2020; 11():1261. PubMed ID: 32695104
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.
Hassan R; Viner JL; Wang QC; Margulies I; Kreitman RJ; Pastan I
J Immunother; 2000; 23(4):473-9. PubMed ID: 10916757
[TBL] [Abstract][Full Text] [Related]
15. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
[TBL] [Abstract][Full Text] [Related]
16. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Weldon JE; Xiang L; Zhang J; Beers R; Walker DA; Onda M; Hassan R; Pastan I
Mol Cancer Ther; 2013 Jan; 12(1):48-57. PubMed ID: 23136186
[TBL] [Abstract][Full Text] [Related]
17. A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.
Liu W; Onda M; Kim C; Xiang L; Weldon JE; Lee B; Pastan I
Protein Eng Des Sel; 2012 Jan; 25(1):1-6. PubMed ID: 22101015
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice.
Manning ML; Mason-Osann E; Onda M; Pastan I
J Immunol; 2015 Feb; 194(4):1695-701. PubMed ID: 25560410
[TBL] [Abstract][Full Text] [Related]
19. New Life for Immunotoxin Cancer Therapy.
Hassan R; Alewine C; Pastan I
Clin Cancer Res; 2016 Mar; 22(5):1055-8. PubMed ID: 26463707
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
